UBS lowered the firm’s price target on Veracyte (VCYT) to $42 from $49 and keeps a Buy rating on the shares. UBS sees durable growth in Veracyte’s core products, as well as long-term growth potential from minimal residual disease testing, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue